INT310951

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 2
Disease Relevance 2.71
Pain Relevance 0.06

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

generation of precursor metabolites and energy (DLST) mitochondrion (DLST) small molecule metabolic process (DLST)
plasma membrane (DLST) nucleus (DLST) transferase activity, transferring acyl groups (DLST)
DLST (Homo sapiens)
Pain Link Frequency Relevance Heat
Paracetamol 5 57.76 Quite High
Inflammation 2 5.00 Very Low Very Low Very Low
corticosteroid 1 5.00 Very Low Very Low Very Low
methotrexate 1 5.00 Very Low Very Low Very Low
Paresthesia 1 5.00 Very Low Very Low Very Low
fluoxetine 1 5.00 Very Low Very Low Very Low
cocaine 1 5.00 Very Low Very Low Very Low
backache 1 5.00 Very Low Very Low Very Low
addiction 1 5.00 Very Low Very Low Very Low
peripheral neuropathy 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Pneumonia 13 99.96 Very High Very High Very High
Mucositis 6 99.84 Very High Very High Very High
Drug Eruptions 3 99.56 Very High Very High Very High
Neutropenia 13 99.04 Very High Very High Very High
Toxicity 45 96.00 Very High Very High Very High
Stomatitis 5 93.28 High High
Thrombocytopenia 12 90.56 High High
Pulmonary Eosinophilia 11 90.08 High High
Anastomotic Leak 1 89.24 High High
Drug Hypersensitivity 4 85.92 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In contrast to drug eruption, the usefulness of a DLST for identifying the offending drug in drug-induced pneumonia has not been established.
Positive_regulation (induced) of DLST associated with drug eruptions and pneumonia
1) Confidence 0.43 Published 2007 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2873625 Disease Relevance 0.94 Pain Relevance 0.06
Given the evidences of a different toxicity profile, PLD safety has been also investigated in combinations involving two or even three agents:21–64 in the dose-finding studies exploring combinations of PLD with cisplatin (CDDP) (Table 2), the DLTs were mostly represented by mucositis, and also neutropenia when CDDP was used at doses > 60 mg/m2 every 28 days.21,22 Similarly, when combining PLD with carboplatin (JM8), DLTs consisting in stomatitis/mucositis were documented at PLD doses > 50 mg/m2, while thrombocytopenia was the most frequently reported DLT for lower PLD doses, with the exception of the study by Hamilton et al.25
Positive_regulation (represented) of DLTs associated with neutropenia, toxicity, stomatitis, mucositis and thrombocytopenia
2) Confidence 0.09 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2952486 Disease Relevance 1.77 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox